TY - JOUR
T1 - NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma
AU - Schild, Tanya
AU - McReynolds, Melanie R.
AU - Shea, Christie
AU - Low, Vivien
AU - Schaffer, Bethany E.
AU - Asara, John M.
AU - Piskounova, Elena
AU - Dephoure, Noah
AU - Rabinowitz, Joshua D.
AU - Gomes, Ana P.
AU - Blenis, John
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2021/6/15
Y1 - 2021/6/15
N2 - Metabolic adaptations and the signaling events that control them promote the survival of pancreatic ductal adenocarcinoma (PDAC) at the fibrotic tumor site, overcoming stresses associated with nutrient and oxygen deprivation. Recently, rewiring of NADPH production has been shown to play a key role in this process. NADPH is recycled through reduction of NADP+ by several enzymatic systems in cells. However, de novo NADP+ is synthesized only through one known enzymatic reaction, catalyzed by NAD+ kinase (NADK). In this study, we show that oncogenic KRAS promotes protein kinase C (PKC)-mediated NADK phosphorylation, leading to its hyperactivation, thus sustaining both NADP+ and NADPH levels in PDAC cells. Together, our data show that increased NADK activity is an important adaptation driven by oncogenic signaling. Our findings indicate that NADK could serve as a much-needed therapeutic target for PDAC.
AB - Metabolic adaptations and the signaling events that control them promote the survival of pancreatic ductal adenocarcinoma (PDAC) at the fibrotic tumor site, overcoming stresses associated with nutrient and oxygen deprivation. Recently, rewiring of NADPH production has been shown to play a key role in this process. NADPH is recycled through reduction of NADP+ by several enzymatic systems in cells. However, de novo NADP+ is synthesized only through one known enzymatic reaction, catalyzed by NAD+ kinase (NADK). In this study, we show that oncogenic KRAS promotes protein kinase C (PKC)-mediated NADK phosphorylation, leading to its hyperactivation, thus sustaining both NADP+ and NADPH levels in PDAC cells. Together, our data show that increased NADK activity is an important adaptation driven by oncogenic signaling. Our findings indicate that NADK could serve as a much-needed therapeutic target for PDAC.
UR - http://www.scopus.com/inward/record.url?scp=85107939399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107939399&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2021.109238
DO - 10.1016/j.celrep.2021.109238
M3 - Article
C2 - 34133937
AN - SCOPUS:85107939399
SN - 2211-1247
VL - 35
JO - Cell Reports
JF - Cell Reports
IS - 11
M1 - 109238
ER -